Propylene Glycol
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Propylene Glycol: From Dry Eye Syndrome to Bronchitis
One-Sentence Summary
Propylene glycol is a solvent and lubricant used in ocular lubricant products, originally associated with dry eye syndrome and xerophthalmia. The TxGNN model predicts it may be effective for bronchitis, but the evidence does not support this: there are 0 clinical trials and 3 publications, and those publications mostly point to possible airway harm rather than benefit.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Dry eye syndrome, xerophthalmia |
| Predicted New Indication | Bronchitis |
| TxGNN Prediction Score | 0.9990 |
| Evidence Level | L5 |
| Canada Market Status | Marketed (marketed DINs: 5 of 5) |
| Number of DINs | 5 (marketed: 5) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on known information, propylene glycol is used as an ocular lubricant and as a solvent or excipient in many formulations. Its use in dry eye is as a moisturising and lubricating agent, not as a disease-modifying drug.
The data compiled for this report do not support a therapeutic link between dry eye and bronchitis. The retrieved literature discusses propylene glycol as a constituent of e-cigarette liquids and its potential to irritate the airways or worsen lung disease, including asthma and chronic bronchitis. This suggests possible harm rather than benefit. The third paper (quercetin in mice) does not involve propylene glycol as a therapeutic agent.
The high TxGNN score is therefore best read as a network-based prediction without clinical backing.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 26408554 | 2015 | Review | Am J Physiol Lung Cell Mol Physiol | Reviews whether chronic e-cigarette use may cause lung disease, including COPD and chronic bronchitis. Concerns harm, not treatment. |
| 28983782 | 2017 | Review | Curr Allergy Asthma Rep | E-cigarette liquids and aerosols contain airway irritants and may worsen asthma and other lung disease. |
| 20920189 | 2010 | Preclinical (animal) | Respir Res | Quercetin reduced lung inflammation in a COPD mouse model. Propylene glycol is not the therapeutic agent. |
Canada Market Information
| DIN | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 02352699 | RHINARIS NASAL GEL | Not specified | Not specified |
| 02354551 | RHINARIS NASAL MIST | Not specified | Not specified |
| 02321696 | LUBRICANT EYE DROPS/ ARTIFICIAL TEARS | Not specified | Not specified |
| 00551805 | SECARIS | Not specified | Not specified |
| 02242370 | SOOTHE DRY EYES | Not specified | Not specified |
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests on a model score alone (Evidence Level L5). No clinical trials exist for bronchitis, and the available literature raises a possible airway-irritation concern. No therapeutic mechanism is supported.
To proceed, the following is needed:
- Mechanism of action data for propylene glycol
- Health Canada package insert warnings and contraindications, so that safety screening can begin
- Direct clinical or mechanistic evidence for any respiratory benefit, plus a review of inhaled-exposure safety
- Review of other predicted indications. Diabetic retinopathy (L4) has only indirect evidence: one trial that used artificial tears as a comparator for injection pain, and a paper on a different compound, propylene glycol mannate sulfate. The other predictions, mainly cataract types, are model-only with no supporting evidence.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.